Alkaline Phosphatase Anti-WDR68 antibody [EPR8712],Abcam,AB308945

How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

Antibody Labelling, Target Binding Affinity

Conjugate

Alkaline Phosphatase

Platform ID

BAB511555009

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAlkaline Phosphatase Anti-WDR68 antibody [EPR8712]
Cat. No.AB308945
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ConjugationAlkaline Phosphatase
ApplicationAntibody Labelling, Target Binding Affinity
ClonalityMonoclonal
Clone NumberEPR8712
Concentration0.25 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: 50% Glycerol (glycerin, glycerine), 1% BSA, 0.016% Magnesium chloride, 0.001% Zinc chloride
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Involved in craniofacial development. Acts upstream of the EDN1 pathway and is required for formation of the upper jaw equivalent, the palatoquadrate. The activity required for EDN1 pathway function differs between the first and second arches (By similarity). Associates with DIAPH1 and controls GLI1 transcriptional activity. Could be involved in normal and disease skin development. May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex. See full target information DCAF7

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.